Mild persistent asthma: a pragmatic approach

Perera, W.
July 2005
Thorax;Jul2005, Vol. 60 Issue 7, p587
Academic Journal
The article focuses on a study on mild persistent asthma. All patients were given a symptom based asthma treatment plan advising them to use open label budesonide or oral prednisone when their symptoms worsened. There was no significant difference in the primary outcome of change in morning peak flow between the three groups. There were no significant differences in the number of asthma exacerbations or in the asthma related quality of life scores. Providing patients with symptom based treatment plans individually tailored to the severity of their disease permits asthma control with a minimum of medication.


Related Articles

  • Beclometasone/prednisone.  // Reactions Weekly;2/14/2009, Issue 1239, p7 

    The article describes two cases of immediate allergic reactions following treatment with prednisone and beclometasone. The first patient received the prednisone for arthralgia, while the second patient took beclometasone for asthma. The first patient developed oropharyngeal discomfort and oedema...

  • Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Beeh, Kai-Michael; LaForce, Craig; Gahlemann, Martina; Wenz, Arne; Toorawa, Robert; Fležar, Matjaž // Respiratory Research;Jul2015, Vol. 16 Issue 1, p1 

    Background: A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks' treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily dose) versus placebo...

  • Management of acute asthma.  // British Medical Journal;10/11/1975, Vol. 4 Issue 5988, p65 

    Focuses on the management of acute asthma. Treatment option for patients; Effect of sedatives and tranquilizers in severe asthma; Administration of prednisone after intravenous therapy.

  • Asmaven.  // Royal Society of Medicine: Medicines;2002, p89 

    The article presents information on Asmaven, a proprietary, prescription-only preparation of the beta-receptor stimulant salbutamol. It can be used as a bronchodilator in reversible obstructive airways disease, as an asthmatic treatment. It is available as tablets and an aerosol.

  • Inhalation devices.  // CMAJ: Canadian Medical Association Journal;9/13/2005 Supplement, Vol. 173, pS39 

    The article examines the use of inhalers such as Hydrofluoroalkane (HFA) propellants in treating asthma. HFA-propellant pressurized metered-dose inhalers (pMDI) have been to be effective among adults and children but differences in the metering valve plus actuator would only result to the...

  • Montelukast for management of persistent asthma. APGAR, BARBARA // American Family Physician;12/1/1998, Vol. 58 Issue 9, p2137 

    Presents an abstract of an article regarding the therapeutic use of Montelukast sodium for the treatment of asthma as presented at the `Medical Letters Drugs Therapy' journal dated July 17, 1998. Mechanism of action; Clinical trial on the drug; Price.

  • Considerations in the long-term management of asthma in ambulatory patients. Williams, Dennis M. // American Journal of Health-System Pharmacy;5/15/2006, Vol. 63 Issue 10, pS14 

    Purpose. The goals of treatment and drug therapies used for long-term asthma control, classification of the disease by severity, and treatment based on severity are reviewed, with an emphasis on recent controversies in treatment approach and safety concerns. Summary. Patient education and...

  • Asthma: Intramuscular vs. Oral Methylprednisolone. Miller, Karl E. // American Family Physician;4/1/2005, Vol. 71 Issue 7, p1414 

    Discusses research being done on the treatment of asthma exacerbations. Reference to a study by M. Lahn et al, published in the August 2004 issue of the journal "Chest"; Procedures for the study; Efficacy of intramuscular methylprednisolone in treating asthma exacerbations; Adverse effects of...

  • Last gasp for Primatene Mist?  // Consumer Reports;Jul2011, Vol. 76 Issue 7, p13 

    The article reports on Primatene Mist, an inhaler used to treat the effects of asthma, that is sold without a prescription. The article reports that Primatene Mist will be removed from the market on January 1, 2012 due to the chlorofluorocarbons it contains. The impact on those who rely on the...


Read the Article


Sign out of this library

Other Topics